Harvard Bioscience
HBIO
68 hedge funds and large institutions have $73.2M invested in Harvard Bioscience in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 23 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.11% less ownership
Funds ownership: 6.42% → 6.31% (-0.11%)
2% less capital invested
Capital invested by funds: $74.7M → $73.2M (-$1.49M)
4% less funds holding
Funds holding: 71 → 68 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
35% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.27M |
| 2 |
HP
Harvey Partners
Tarrytown,
New York
|
+$775K |
| 3 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
+$577K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$416K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$325K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
-$1.36M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.35M |
| 3 |
ECM
Engine Capital Management
New York
|
-$959K |
| 4 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$709K |
| 5 |
RA
Royce & Associates
New York
|
-$623K |
HBIO Hedge Fund Activity: Q4 2019 in Review
68 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2019, worth a combined $73.2M — down 2% from $74.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of HBIO and 6 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 15 added.
The largest buyer was Kennedy Capital Management, adding an estimated $1.27M. The largest seller was Fondren Management, cutting an estimated $1.36M.
- 68 institutional investors held Harvard Bioscience (HBIO) as of Q4 2019, down from 71 in Q3 2019.
- Funds reported $73.2M of Harvard Bioscience stock for Q4 2019, down 2% quarter-over-quarter.
- 6 funds opened new Harvard Bioscience positions in Q4 2019 and 9 closed out, a net change of -3 holders.
- The largest Harvard Bioscience buyer in Q4 2019 was Kennedy Capital Management, an estimated $1.27M added.
- The largest Harvard Bioscience seller in Q4 2019 was Fondren Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q4 2019.